eGene's Genetic Analyzer Demonstrates its Technology for Gene Expression Market
News Jun 01, 2006
eGene Inc. has announced that its analyzer has demonstrated automated high-throughput RNA quality control analysis for the gene expression market. The application note is published in the May issue of Bioscience Technology.
Dr. Ming S. Liu, acting CEO of eGene, noted, "Gene expression has become a mainstream technique in biology, medicine and drug development."
"Our HDA-GT12 platform is a revolutionary technology for RNA quality control checking. A researcher can check RNA quality for 12 samples in 10 minutes and 96 samples in less than 90 minutes."
"Our compact, automated high throughput digital HDA-GT12 genetic analyzer can play a major role in the gene expression market," he continued.
"We can see increased demand in the current market, and more customers are integrating our HDA-GT12 system in their gene expression research."
The HDA-GT12™ Genetic Analyzer analyzes the genetic fingerprints of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp).
The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA.
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018